NCT06102928View on ClinicalTrials.gov

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
DRUG

Combined therapy of anlotinib and aumolertinib

Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.

Trial Locations (1)

Unknown

RECRUITING

First Affiliated Hospital of Kunming University, Kunming

All Listed Sponsors
lead

Kunming Medical University

OTHER